<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) pathway is a master regulator in energy metabolism and may be related to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> predicts <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, whereas <z:chebi fb="0" ids="6801">metformin</z:chebi> usage is associated with reduced <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="2" pm="."><plain>Both <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A1 activate the AMPK signaling pathway </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesize that the anticancer effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> may be particularly evident in type 2 diabetic patients with <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: In a consecutive cohort of 2,658 Chinese type 2 diabetic patients enrolled in the study between 1996 and 2005, who were free of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and not using <z:chebi fb="0" ids="6801">metformin</z:chebi> at enrollment or during 2.5 years before enrollment and who were followed until 2005, we measured biological interactions for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk using relative excess risk as a result of interaction (RERI) and attributable proportion (AP) as a result of interaction </plain></SENT>
<SENT sid="5" pm="."><plain>A statistically significant RERI &gt;0 or AP &gt;0 indicates biological interaction </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During 13,808 person-years of follow-up (median 5.51 years), 129 patients developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> &lt;1.0 mmol/L was associated with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk among those who did not use <z:chebi fb="0" ids="6801">metformin</z:chebi>, but the association was not significant among those who did </plain></SENT>
<SENT sid="8" pm="."><plain>Use of <z:chebi fb="0" ids="6801">metformin</z:chebi> was associated with reduced <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in patients with <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> &lt;1.0 mmol/L and, to a lesser extent, in patients with <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ≥ 1.0 mmol/L </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> &lt;1.0 mmol/L plus nonuse of <z:chebi fb="0" ids="6801">metformin</z:chebi> was associated with an adjusted hazard ratio of 5.75 (95% CI 3.03-10.90) compared with <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ≥ 1.0 mmol/L plus use of <z:chebi fb="0" ids="6801">metformin</z:chebi>, with a significant interaction (AP 0.44 [95% CI 0.11-0.78]) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The anticancer effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> was most evident in type 2 diabetic patients with <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> </plain></SENT>
</text></document>